Serono Sues Cell Genesys Over TKT Gene Activation Patent

Law360 (September 1, 2004, 12:00 AM EDT) -- A subsidiary of Switzerland’s Serono has sued Transkaryotic Therapies (TKT) licensee Cell Genesys, alleging that gene activation technology used in the production of TKT’s biological drugs infringes a U.S. patent.

Serono’s subsidiary, Applied Research Systems, filed the amended complaint in the U.S. District Court for the District of Massachusetts, claiming infringement of its U.S. patent No. 5,272,071.

In the original complaint, Serono appealed a U.S. Patent and Trademark Office decision that 34 of the claims of the '071 patent are invalid.

Serono and Cell Genesys were...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.